NEXT


Noven products are sold in all
major international markets.

Over the past decade, Noven’s technological advantages have attracted strategic partners who seek to offer leading-edge transdermal therapies, including:

Novogyne Pharmaceuticals In the U.S., Noven has licensed its menopausal hormone therapy patches to Novogyne Pharmaceuticals, a women’s health products company that is a joint venture between Noven and Novartis Pharmaceuticals Corporation. Vivelle-Dot®, Novogyne’s lead product, is the most dispensed transdermal estrogen therapy in the U.S.
Novartis Pharma AG In Europe, Noven has licensed its HT patches to Novartis Pharma AG, a global leader in transdermal HT. Estradot®, the international version of Vivelle-Dot®, is currently available in European markets.
Sanofi-aventis Noven has licensed its HT patches to Sanofi-aventis for marketing in Japan.
Apotex Corp. In the U.S., Noven (through Hisamitsu) has licensed its Fentanyl Transdermal System to Apotex Corp., one of the top 10 generic pharmaceutical companies in the U.S.

For additional information, contact Noven Business Development.

 

Copyright © 2012 Noven Pharmaceuticals, Inc. All rights reserved.